Trial Profile
A Phase I Multicenter Trial Of Intratumoral/Interstitial Therapy With HN66000, NC66000 (TransMID) In Patients Between 5 and 18 Years Of Age With Progressive Or Recurrent Glioblastoma Multiforme Or Anaplastic Astrocytoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs XR 311 (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma
- Focus Adverse reactions
- 19 Sep 2005 New trial record.